Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Urticaria Market?

In the past few years, there has been a significant expansion in the urticaria market. It is projected to surge from $4.03 billion in 2024 to $4.77 billion in 2025, marking a compound annual growth rate (CAGR) of 18.2%. Factors contributing to the growth during the historic period include an increase in allergy prevalence, heightened awareness of skin conditions, advances in immunology and biologics technology, a rise in demand for antihistamines, and enhanced diagnostic techniques.

What Growth Rate Is Forecasted for the Urticaria Market by 2029?

The market size for urticaria is anticipated to experience a rapid surge in the coming years, reaching an estimated value of $9.23 billion in 2029 with a compound annual growth rate (CAGR) of 18.0%. This upswing for the projected period can be linked to the increasing incidences of chronic urticaria, growing acceptance of biologic treatments, an upsurge in investments in dermatology studies, broader access to advanced allergy diagnostics, and progressive developments in personalized medicine. Notable market trends for the forecasted period encompass AI-driven diagnostic instruments, emerging novel biologics, advancements in tailored immunotherapy, wearable devices for skin monitoring, and the utilization of telemedicine for the management of allergies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23554&type=smp

Which Key Companies Are Shaping the Future of the Urticaria Market?

Major companies operating in the urticaria market are Sanofi S.A., Novartis AG, GlaxoSmithKline PLC, Roche Holding AG, Viatris Inc., Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Incyte Corporation, Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd, Cipla Ltd., Amneal Pharmaceuticals Inc, Glenmark Pharmaceuticals Ltd, Torrent Pharmaceuticals, Almirall S.A., Argenx SE, BioCryst Pharmaceuticals Inc., Pharvaris NV, Revolution Medicines Inc., Allakos.

Which Factors Are Driving Demand in the Urticaria Industry?

The expansion of the urticaria market is likely to be fueled by the rising awareness and treatment of skin diseases. The escalation in pollution contributes to a higher incidence of skin allergies and disorders, thereby demanding better awareness and more advanced remedies. Urticaria plays a significant role in raising this awareness of skin diseases and their treatment by displaying immune system reactions, promoting research, optimizing diagnostics, and propelling the development of specialized therapies. In February 2024, The Skin Cancer Foundation, a nonprofit organization based in the US, indicated that skin cancer affects one in five Americans by the age of 70, and examines more than two deaths each hour within the U.S. This statistics emphasizes the crucial necessity for preventative strategies as experiencing five or more sunburns doubles the melanoma risk. Hence, the surge in skin disease awareness and treatment is stimulating the growth of the urticaria market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23554&type=smp

How Is the Urticaria Market Segmented by Several Divisions?

The urticaria market covered in this report is segmented –

1) By Type: Acute Urticaria, Chronic Urticaria

2) By Drug Class: Antihistamines, Anti-inflammation Medications, Antidepressants, Monoclonal Antibodies, Other Drug Classes

3) By Route of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Acute Urticaria: Allergic Urticaria, Infectious Urticaria, Drug-Induced Urticaria, Contact Urticaria

2) By Chronic Urticaria: Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU)

What are the Emerging Market Trends Driving the Growth of the Urticaria Industry?

Notable corporations in the urticaria market are prioritizing the creation of groundbreaking solutions such as mast cell inhibitor antibodies. Their aim is to create a novel therapeutic approach for managing chronic spontaneous urticaria by targeting mast cell activation. A mast cell inhibitor antibody essentially operates as a targeted monoclonal antibody that detains the activation or degranulation of mast cells by inhibiting particular receptors or signalling pathways. As a result, it reduces allergic reactions, inflammation, and other dysfunctions mediated by mast cells. For example, Allakos Inc., an American biotechnological company, in May 2024 publicized the launch of a Phase 1 clinical trial for AK006, designed with the purpose to cure chronic spontaneous urticaria (CSU). This revolutionary therapy places its targets on both IgE-dependent and IgE-independent mast cell activation routes. It renders the potential for larger efficacy in patients who are resistant to antihistamines or previous biologic treatments. By selectively inhibiting mast cell activity via the Siglec-6 receptor, AK006 sets about providing a more widespread and enduring solution for CSU management. This highlights a crucial leap in the urticaria treatment as well as immunotherapy research field.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/urticaria-global-market-report

Which Regions Are Driving Growth in the Urticaria Market?

North America was the largest region in the urticaria market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23554

This Report Delivers Insight On:

1. How big is the urticaria market, and how is it changing globally?

2. Who are the major companies in the urticaria market, and how are they performing?

3. What are the key opportunities and risks in the urticaria market right now?

4. Which products or customer segments are growing the most in the urticaria market?

5. What factors are helping or slowing down the growth of the urticaria market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model